Latest Memorial Sloan–Kettering Cancer Center Stories
 A new study sheds light on a little understood biological process called quiescence, which enables blood-forming stem cells to exist in a dormant or inactive state in which they are not growing or dividing. According to the study's findings, researchers identified the genetic pathway used to maintain a cell's quiescence, a state that allows bone marrow cells to escape the lethal effects of standard cancer treatments.Researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) found...
Researchers have developed a new generation of microscopic particles for molecular imaging, constituting one of the first promising nanoparticle platforms that may be readily adapted for tumor targeting and treatment in the clinic.According to the investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) and Cornell University, these particles are biologically safe, stable, and small enough to be easily transported across the body's structures and efficiently excreted through the urine....
SAN DIEGO, Dec. 18 /PRNewswire/ -- MabVax Therapeutics Inc., a privately held immunotherapeutics discovery and development company focused on the development and commercialization of novel immunotherapies for the treatment of cancer, announced the company has received two grant awards from the National Cancer Institute under the Small Business Technology Transfer Program (STTR) totaling $400,000. The first award is aimed at supporting a Pilot Trial With a Tetravalent Conjugate Vaccine...
Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the world leader in the development of a new class of small molecule compounds based on endogenous adrenal steroid hormones, announced that it has commenced a Phase I/II clinical trial with its oral drug candidate APOPTONE(TM) (HE3235) in late-stage prostate cancer patients who have failed hormone therapy and at least one round of chemotherapy treatment. The Phase I/II open-label dose ranging study, being conducted with the Prostate Cancer...
Researchers have found that therapeutic cloning can be used to treat Parkinson's disease in mice. In their latest study, a team of researchers at Memorial Sloan-Kettering Cancer Center showed for the first time that therapeutic cloning, or somatic-cell nuclear transfer, was a successful method of treating disease in the same subject from which the initial cells were taken."It demonstrated what we suspected all along -- that genetically matched tissue works better," said Viviane...
The Ralph Lauren Center for Cancer Care and Prevention and the Amgen Foundation today announced the launch of the Harold P. Freeman Patient Navigation Training Institute. Made possible by a generous $2.5 million leadership grant over three years from the Amgen Foundation, the Institute will provide training to individuals nationwide interested in becoming patient navigators, as well as health care administrators developing patient navigation programs throughout the country and across...
Ichor Medical Systems announced today it has received FDA approval to conduct a Phase I clinical trial of a melanoma vaccine to be administered to patients utilizing a novel delivery technology. The vaccine, which was developed by Memorial Sloan-Kettering Cancer Center scientists, consists of DNA encoding a form of the tyrosinase protein. This protein is found broadly in melanoma cells and is a promising target for immunotherapy. The vaccine will be administered with the Ichor...
NEW YORK, April 26 /PRNewswire/ -- "Imagine if Eastern Philosophy harmonized with Western medical practice and if we treated the patient with the same passion with which we treat the disease ... When my husband Stephan, and best friend Lynn Kohlman were stricken with cancer, so much was missing from their care. They needed the powerful science from Western medicine, but they also needed the healing that can only be accessed from the heart, spirit and alternative...
NEW YORK, September 21, 2005 "“ Women with a strong family history of breast cancer but who don't have breast cancer genetic mutations can now be reassured that they are not at increased risk for ovarian cancer, according to a new study by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC). The work, published in the September 21, 2005, issue of the Journal of the National Cancer Institute, is one of the first prospective studies to allow doctors to tailor ovarian cancer...
NEW YORK, August 4, 2005 -- Prostate cancer, the second leading cause of cancer death for men in the United States, is caused by changes in several tummor suppressor genes including PTEN and p53. Up to 70 percent of men with prostate cancer have lost one copy of the PTEN gene at the time of diagnosis, and p53 is absent in a high number of patients with advanced prostate cancer. Scientists at Memorial Sloan-Kettering Cancer Center have found an unexpected effect of the interaction of these two...
